Tonix Pharmaceuticals to Participate in BIO CEO & Investor Conference
February 07, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that Seth...
Tonix Pharmaceuticals Initiates Enrollment in Clinical Trial of TNX-2100, a Diagnostic Skin Test to Measure Functional T Cell Immunity to SARS-CoV-2
January 11, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Potential Uses Include: Biomarker of Immunity to SARS-CoV-2; Personalized Approach to Timing COVID-19 Vaccine Boosters; Public Health Surveillance; and Serving as an Endpoint for COVID-19 Vaccine...
Tonix Pharmaceuticals to Participate in Upcoming January Conferences
January 05, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that Seth...
Tonix Pharmaceuticals Announces Exclusive Option and Research Collaboration with Kansas State University to Develop LNP-Free mRNA Vaccines
January 04, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
New Zinc Nanoparticle (ZNP) Technology Replaces the Lipid Nanoparticle (LNP) Technology Employed in Current mRNA COVID-19 Vaccines ZNP Technology Expected to Improve mRNA Vaccine Temperature...
Tonix Pharmaceuticals Added to the Nasdaq Biotechnology Index
December 15, 2021 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it has...
Tonix Pharmaceuticals Announces IND Clearance for Skin Test (TNX-2100) to Measure SARS-CoV-2 Exposure and T Cell Immunity
December 14, 2021 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
First-in-Human Study Expected to be Initiated in the First Quarter of 2022 An Approved Test Would Lead to Identification of People Requiring Vaccine Boosters CHATHAM, N.J., Dec. 14, 2021 (GLOBE...
Tonix Pharmaceuticals Announces Research Collaboration with Columbia University to Study Recombinant Trefoil Factor 2 (rTFF2)-Based Therapy (TNX-1700) for Gastric and Colorectal Cancers
December 13, 2021 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
TNX-1700 is Under Development as Monotherapy and in Combination with Anti-PD1 Checkpoint Inhibitor Therapy in Animal Models of Two Challenging Cancers In Mouse Models, rTFF2 Detoxifies the Tumor...
Tonix Pharmaceuticals Announces FDA Clearance of the IND for Potentiated Intranasal Oxytocin (TNX-1900) for the Prevention of Migraine Headache in Chronic Migraineurs
November 23, 2021 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Approximately Four Million in U.S. Suffer from Chronic Migraine Development of TNX-1900 Also Planned for Treatment of Episodic Migraine, Craniofacial Pain and Insulin Resistance CHATHAM, N.J.,...
Tonix Pharmaceuticals Announces Publication of Paper on Antiviral SARS-CoV-2 Inhibitor, TNX-3500, in JCI Insight
November 22, 2021 16:05 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the...
Tonix Pharmaceuticals Announces Issuance of U.S. Patent for Use of TNX-1700, a Stabilized Recombinant Form of Trefoil Factor 2 (TFF2), for Treating Gastric and Pancreatic Cancers
November 15, 2021 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the U.S....